JPWO2021255127A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021255127A5 JPWO2021255127A5 JP2022577390A JP2022577390A JPWO2021255127A5 JP WO2021255127 A5 JPWO2021255127 A5 JP WO2021255127A5 JP 2022577390 A JP2022577390 A JP 2022577390A JP 2022577390 A JP2022577390 A JP 2022577390A JP WO2021255127 A5 JPWO2021255127 A5 JP WO2021255127A5
- Authority
- JP
- Japan
- Prior art keywords
- relaxin
- heterodimeric fusion
- chain
- polypeptide
- linked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025279747A JP2026053559A (ja) | 2020-06-17 | 2025-12-24 | ヘテロ二量体リラキシン融合物及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063040250P | 2020-06-17 | 2020-06-17 | |
| US63/040,250 | 2020-06-17 | ||
| PCT/EP2021/066309 WO2021255127A1 (en) | 2020-06-17 | 2021-06-16 | Heterodimeric relaxin fusions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025279747A Division JP2026053559A (ja) | 2020-06-17 | 2025-12-24 | ヘテロ二量体リラキシン融合物及びその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023530335A JP2023530335A (ja) | 2023-07-14 |
| JP2023530335A5 JP2023530335A5 (https=) | 2024-09-19 |
| JPWO2021255127A5 true JPWO2021255127A5 (https=) | 2024-09-19 |
| JP7797423B2 JP7797423B2 (ja) | 2026-01-13 |
Family
ID=76584509
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022577390A Active JP7797423B2 (ja) | 2020-06-17 | 2021-06-16 | ヘテロ二量体リラキシン融合物及びその使用 |
| JP2025279747A Pending JP2026053559A (ja) | 2020-06-17 | 2025-12-24 | ヘテロ二量体リラキシン融合物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025279747A Pending JP2026053559A (ja) | 2020-06-17 | 2025-12-24 | ヘテロ二量体リラキシン融合物及びその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11795205B2 (https=) |
| EP (1) | EP4168434A1 (https=) |
| JP (2) | JP7797423B2 (https=) |
| KR (1) | KR20230024994A (https=) |
| CN (1) | CN115916813B (https=) |
| AR (1) | AR125007A1 (https=) |
| AU (3) | AU2021290997C1 (https=) |
| BR (1) | BR112022025019A2 (https=) |
| CA (1) | CA3186143A1 (https=) |
| CL (1) | CL2022003578A1 (https=) |
| CO (1) | CO2023000038A2 (https=) |
| CR (1) | CR20230015A (https=) |
| EC (1) | ECSP23002960A (https=) |
| IL (1) | IL298786A (https=) |
| MX (1) | MX2022016340A (https=) |
| TW (1) | TWI899263B (https=) |
| WO (1) | WO2021255127A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023086913A2 (en) * | 2021-11-11 | 2023-05-19 | Tectonic Therapeutic, Inc. | Relaxin-2 fusion protein analogs and methods of using same |
| EP4524156A4 (en) | 2022-05-07 | 2025-10-22 | Beijing Tuo Jie Biopharmaceutical Co Ltd | RELAXIN FUSION PROTEIN OR ANALOGUE AND ITS MEDICAL USE |
| US20260103501A1 (en) * | 2022-07-15 | 2026-04-16 | Nutcracker Therapeutics, Inc. | MRNA Therapies Including SIRP-ALPHA |
| TW202438534A (zh) | 2022-12-09 | 2024-10-01 | 瑞典商阿斯特捷利康公司 | 使用異二聚物鬆弛素融合體的給藥方案 |
| AU2024232947A1 (en) | 2023-03-03 | 2025-10-16 | Astrazeneca Ab | Pharmaceutical formulation comprising heterodimeric relaxin fusion proteins and uses thereof |
| KR20260035823A (ko) | 2023-05-18 | 2026-03-13 | 테크토닉 오퍼레이팅 컴퍼니 인코포레이티드 | 렐락신-2 융합 단백질 유사체 및 이를 사용하는 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US8389475B2 (en) * | 2009-08-10 | 2013-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Relaxin analogs |
| PL2635607T3 (pl) * | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| EP2726502A1 (en) * | 2011-07-01 | 2014-05-07 | Bayer Intellectual Property GmbH | Relaxin fusion polypeptides and uses thereof |
| CA2854233C (en) | 2011-11-04 | 2020-05-12 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| AR094147A1 (es) * | 2012-12-27 | 2015-07-15 | Bayer Pharma Aktiengellschaft | Polipeptidos de fusion con actividad de relaxina y sus usos |
| RU2729467C2 (ru) * | 2014-05-28 | 2020-08-06 | Займворкс Инк. | Модифицированные антигенсвязывающие полипептидные конструкции и их применение |
| WO2017100540A2 (en) | 2015-12-09 | 2017-06-15 | The California Institute For Biomedical Research | Relaxin immunoglobulin fusion proteins and methods of use |
| CN110225924B (zh) * | 2017-01-25 | 2024-04-02 | 免疫医疗有限公司 | 松弛素融合多肽及其用途 |
-
2021
- 2021-06-16 MX MX2022016340A patent/MX2022016340A/es unknown
- 2021-06-16 IL IL298786A patent/IL298786A/en unknown
- 2021-06-16 CN CN202180042080.5A patent/CN115916813B/zh active Active
- 2021-06-16 KR KR1020237001632A patent/KR20230024994A/ko active Pending
- 2021-06-16 EP EP21734103.1A patent/EP4168434A1/en active Pending
- 2021-06-16 BR BR112022025019A patent/BR112022025019A2/pt unknown
- 2021-06-16 AU AU2021290997A patent/AU2021290997C1/en active Active
- 2021-06-16 WO PCT/EP2021/066309 patent/WO2021255127A1/en not_active Ceased
- 2021-06-16 CA CA3186143A patent/CA3186143A1/en active Pending
- 2021-06-16 US US17/348,825 patent/US11795205B2/en active Active
- 2021-06-16 CR CR20230015A patent/CR20230015A/es unknown
- 2021-06-16 JP JP2022577390A patent/JP7797423B2/ja active Active
- 2021-06-17 TW TW110122051A patent/TWI899263B/zh active
- 2021-06-17 AR ARP210101647A patent/AR125007A1/es unknown
-
2022
- 2022-12-15 CL CL2022003578A patent/CL2022003578A1/es unknown
-
2023
- 2023-01-03 CO CONC2023/0000038A patent/CO2023000038A2/es unknown
- 2023-01-16 EC ECSENADI20232960A patent/ECSP23002960A/es unknown
- 2023-07-01 US US18/346,205 patent/US12187774B2/en active Active
-
2024
- 2024-01-05 AU AU2024200074A patent/AU2024200074B2/en active Active
- 2024-11-25 US US18/958,082 patent/US20250230214A1/en active Pending
-
2025
- 2025-10-20 AU AU2025252658A patent/AU2025252658A1/en active Pending
- 2025-12-24 JP JP2025279747A patent/JP2026053559A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5767260A (en) | Antigen-binding fusion proteins | |
| TWI648401B (zh) | 生長分化因子１５（ｇｄｆ－１５）構築體 | |
| JP2023085476A5 (https=) | ||
| JP2017538395A5 (https=) | ||
| JP2021510162A5 (https=) | ||
| BR112014015018A2 (pt) | moléculas de anticorpo biespecífico e seu método de produção, bem como composição farmacêutica e molécula de ácido nucleico | |
| CN118121696A (zh) | 靶向骨的抗体 | |
| JPH04502408A (ja) | ＩＬ―２レセプターのｐ５５ Ｔａｃタンパク質に特異的なキメラ免疫グロブリン | |
| CN104710535B (zh) | 重组人g-csf二聚体及其在治疗神经系统疾病中的用途 | |
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| JP2016510755A5 (https=) | ||
| JPH07504808A (ja) | Ｃｄｒをグラフトしたヒト化キメラｔ細胞抗体 | |
| JP2019519527A (ja) | 操作されたＦｃコンストラクトに関する組成物及び方法 | |
| JP2021534220A5 (https=) | ||
| WO1997049429A1 (en) | Genetically engineered immunoglobulins with specificity for glycated albumin | |
| JPWO2019140050A5 (https=) | ||
| JP2025124718A5 (https=) | ||
| JP7676316B2 (ja) | Ｈｉｖ感染症の処置のためのクロスオーバー二重可変ドメイン（ｃｏｄｖ）フォーマットを使用した三重特異性および／または三価結合性タンパク質 | |
| US20230002460A1 (en) | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same | |
| JPWO2020172605A5 (https=) | ||
| JPWO2021255127A5 (https=) | ||
| US20240327483A1 (en) | Fusion proteins comprising suppression of tumorigenicity 2 or interleukin-33, pharmaceutical compositions, and therapeutic applications | |
| JP2022545234A (ja) | Ｃｄ３とｃｄ２０を標的とする二重特異性抗体及びその使用 | |
| JPWO2020041604A5 (https=) | ||
| EP4559932A1 (en) | Multispecific antibody and use thereof |